Navigation Links
KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
Date:7/22/2009

SpringTree Special Opportunities Fund, LP ("SpringTree") announced today its AU$25,500,000 investment in Prima BioMed Ltd (ASX:PRR), an Australian Securities Exchange-listed oncology biotechnology company. KTA Capital acted as the exclusive financial advisor to SpringTree's general partner SpringTree Global Investors, LLC on the transaction. A copy of Prima BioMed Ltd's public announcement follows.

New York (PRWEB) July 22, 2009 -- SpringTree Special Opportunities Fund, LP ("SpringTree") announced today its AU$25,500,000 investment in Prima BioMed Ltd (ASX:PRR), an Australian Securities Exchange-listed oncology biotechnology company. KTA Capital acted as the exclusive financial advisor to SpringTree's general partner SpringTree Global Investors, LLC on the transaction. To view a copy of Prima BioMed Ltd's public announcement please click here http://www.asx.com.au/asxpdf/20090721/pdf/31jn69xw14p8wy.pdf.

About KTA Capital, LLC
KTA Capital is an investment bank headquartered in New York, USA. Its services include international investment banking across a wide range of industries, both in the equity capital and debt markets, as well as M&A advisory. In its business it leverages its relationships with literally hundreds of institutional investors, including hedge funds, mutual funds, private equity funds, venture capital funds, bond funds, mezzanine debt funds, private placement funds, investment advisers, national, regional and international banks, acquisitive industry participants and strategic cornerstone investors, family offices, merchant banks and sovereign wealth funds. KTA Capital is registered as a broker-dealer with the United States Securities and Exchange Commission and is a member of Financial Industry Regulatory Authority, Inc. (" FINRA").

Media Contact:
Eugene Tablis
Tel.: +1 646 707 4177

About SpringTree Global Investors, LLC
SpringTree Global Investors, LLC ( www.springtreegi.com ) is a New York-based asset management company that makes debt and equity investments in public companies around the world with a focus on small-cap and mid-cap companies requiring US$5-US$150 million in debt and/or equity. It invests across a broad range of industries and a wide range of geographies and economic environments.

Contact:
Jeffrey Easton
Tel.: +1 212 255 3552

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2664694.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances
2. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
3. Top CEOs Declare Americas Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership
4. Venture Capitalists to Invest in Promising PA Life Science Companies, Governor Rendell Says
5. Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company
6. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
7. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
8. Merck Serono Launches Strategic Venture Capital Fund
9. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
10. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
11. Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
(Date:4/27/2016)... British Columbia , April 27, 2016 /PRNewswire/ ... oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... im Anschluss an ihre Pressemitteilung vom 13. August ... erhalten hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten ... 4.000.000 Kanadische Dollar zu bringen. Davon wurden 157.900.000 ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... is pleased to announce the appointment of John Tilton as Chief Commercial Officer.  ... Director and one of the founding commercial leaders responsible for the commercialization of ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding the ... , PathSensors deploys the CANARY® test platform for the detection of harmful ...
(Date:4/27/2016)... ... 2016 , ... Global Stem Cells Group CEO Benito Novas announced ... of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received his Ph.D. ... for hematologic disorders and the suppression of graft vs. host disease (GVHD) under UM ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):